Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Akari Therapeutics Plc (NASDAQ: AKTX).

Full DD Report for AKTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: AKTX)

Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brady Corporation (NYSE:BRC), Akari Therapeutics PLC (NASDAQ:AKTX), MTGE...
Source: GlobeNewswire
Date: September, 04 2018 08:30
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Akari Therapeutics, plc -- AKTX
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of securities of Akari Therapeutics,...
Source: GlobeNewswire
Date: August, 20 2018 09:00
Akari Therapeutics net loss improves in Q1
Akari Therapeutics ( AKTX ) Q1 results : Revenues: $0; R&D Expense: $1M (-83.3%); SG&A: $3.3M (+43.5%); Net Loss: ($1.3M) (+89.7%); Loss Per Share: $0.00; Quick Assets: $23.8M (-15.3%). More news on: Akari Therapeutics Plc, Healthcare stocks news, Earnings news and commentary, , ...
Source: SeekingAlpha
Date: August, 17 2018 07:23
Akari Therapeutics reports Q1 results
Akari Therapeutics (NASDAQ: AKTX ): Q1 EPS of $0.00 More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 17 2018 07:04
Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials
Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced Phase II U.S. trial for PNH patien...
Source: GlobeNewswire
Date: August, 17 2018 07:00
Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association
NEW YORK and LONDON, June 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announces it will be presenting a...
Source: GlobeNewswire
Date: June, 15 2018 08:00
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXN’s competition. I have previously reviewed a large number of ALXN’s compet...
Source: SeekingAlpha
Date: May, 31 2018 09:04
Market Trends Toward New Normal in Independent Bank, First Busey, American Public Education, The First Bancshares, Northfield, and Akari Therapeutics - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Independent Bank Corporation (NASDAQ:IBCP), First Busey Corporation (NASDA...
Source: GlobeNewswire
Date: May, 25 2018 08:20
Akari Therapeutics Receives Notice Related to Delay in 20-F Filing
NEW YORK and LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that as a result of its ...
Source: GlobeNewswire
Date: May, 21 2018 08:00
Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases
Stock Monitor: Akari Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on Tetraphase Pharma, Inc. (NASDAQ: TTPH ). If you want access to this report all you need to do is sign up now by clicki...
Source: ACCESSWIRE IA
Date: April, 16 2018 07:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-082.082.07892.111.990118,744
2018-05-171.89821.901.961.8827,383
2017-03-10N/A6.50N/AN/A7
2017-03-096.506.506.536.482,038
2017-03-086.586.506.586.40966,129

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-124595,3298.6132Cover
2018-12-1114,5130.0222Cover
2018-12-0716266324.4344Cover
2018-12-0610,90015,74669.2239Short
2018-12-035002,75218.1686Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AKTX.


About Akari Therapeutics Plc (NASDAQ: AKTX)

Logo for Akari Therapeutics Plc (NASDAQ: AKTX)

Not available

 

Contact Information

 

 

Current Management

  • Gur Roshwalb / CEO
  • Dov Elefant / CFO
  • Pablo Jimenez / CMO

Current Share Structure

  • Market Cap: $22,729,483 - 05/14/2018
  • Issue and Outstanding: 11,776,934 - 12/31/2016

 


Recent Filings from (NASDAQ: AKTX)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 11 2018
Notification that form 20-F will be submitted late
Filing Type: NT 20-FFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 21 2018
Amendment to a previously filed F-3
Filing Type: F-3/AFiling Source: edgar
Filing Date: February, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 06 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 26 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: December, 11 2017
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: December, 08 2017

 

 


Daily Technical Chart for (NASDAQ: AKTX)

Daily Technical Chart for (NASDAQ: AKTX)


Stay tuned for daily updates and more on (NASDAQ: AKTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AKTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AKTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AKTX and does not buy, sell, or trade any shares of AKTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/